Restarting CGRPs for Migraine May Lower Response Rate

Restarting a CGRP monoclonal antibody (mAb) after a gap in treatment may lower response rate, a new study suggests. However, switching to a different mAb may counter this effect.

Related Keywords

Madrid ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Alicia Gonzalez Martinez ,Lars Edvinsson ,Alex Jaimes ,University Hospital ,European Headache Congress ,Lund University Hospital Sweden ,Hospital Universitario De La Princesa ,Hospital Sweden ,Medscape Medical ,Migraine Headache ,Hospitals ,Monoclonal Antibody ,Etuximab ,Ituximab ,Europe ,European ,Receptors ,Headache ,Adverse Effects ,Side Effects ,Clinical Guidelines ,Guidelines ,Clinical Research ,Clinical Trials ,Linical Studies ,Pre Clinical Trial ,Double Blind Study ,Double Blind Studies ,Ingle Blind Study ,Ingle Blind Studies ,Nonsteroidal Anti Inflammatory Drugs ,Nsaids ,Said ,